Danielle Bucco

April 05, 2018

Genomic testing of gastrointestinal tumors can be essential to proper treatment.

January 08, 2018

The role of precision medicine has become a significant area of study, specifically with genomics and liquid biopsies. With the introduction of next-generation sequencing and an improvement in the understanding of molecular alterations, treatments for patients have begun to be individualized.

December 29, 2017

Ferdinandos Skoulidis, M.D., Ph.D. highlights potential treatment options for KRAS-mutated lung cancer and explores developments in biomarker research in other areas in the field.

December 26, 2017

When combined with other regimens in the treatment of patients with bladder cancer, immunotherapy has been shown to be beneficial, according to Arjun Balar, M.D.

December 26, 2017

The variety of treatment options now available for non-small cell lung cancer (NSCLC) — including checkpoint inhibitors and targeted therapies — presents challenges in choosing the right treatment plan.

December 22, 2017

Imfinzi (durvalumab), a PD-L1 inhibitor, is being reviewed for a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) for the treatment of patients with stage 3, unresectable non-small cell lung cancer (NSCLC). The sBLA is in light of positive progression-free survival (PFS) results from the phase 3 PACIFIC trial.

December 10, 2017

Chronic pain is a serious side effect of many cancer treatments. Medical marijuana is currently being suggested as an alternative option to traditional opioid medications.

November 27, 2017

“The very exciting field of checkpoint inhibitors is still evolving, and we are trying to understand where they fit in the world of CRC therapy,” said McCollum, a hematologist and medical oncologist at Texas Oncology.

November 08, 2017

New treatment regimens may be hitting the scene of myeloma treatment.

November 06, 2017

Alfred L. Garfall lends insight as to what is new for myeloma treatment.